Brookstone Capital Management Grows Holdings in Johnson & Johnson (NYSE:JNJ)

Brookstone Capital Management increased its position in Johnson & Johnson (NYSE:JNJ – Get Rating) by 0.9% in the 4th quarter, according to its most recent 13F filing with the Securities and Exchange Commission. The institutional investor owned 57,325 shares of the company’s stock after acquiring an additional 491 shares during the quarter. Brookstone Capital Management’s holdings in Johnson & Johnson were worth $10,333,000 at the end of the most recent quarter.

Several other hedge funds and other institutional investors also recently added to or reduced their stakes in the company. Nexus Investment Management ULC increased its holdings in Johnson & Johnson by 16.1% in the 4th quarter. Nexus Investment Management ULC now owns 8,676 shares of the company’s stock worth $1,533,000 after acquiring an additional 1,200 shares in the last quarter. Independence Bank of Kentucky increased its holdings in Johnson & Johnson by 3.2% in the 4th quarter. Independence Bank of Kentucky now owns 24,812 shares of the company’s stock worth $4,383,000 after acquiring an additional 780 shares in the last quarter. CGN Advisors LLC increased its holdings in Johnson & Johnson by 36.9% in the 4th quarter. CGN Advisors LLC now owns 17,071 shares of the company’s stock worth $3,016,000 after acquiring an additional 4,599 shares in the last quarter. MinichMacGregor Wealth Management LLC grew its holdings in Johnson & Johnson by 4.7% during the 4th quarter. MinichMacGregor Wealth Management LLC now owns 1,734 shares of the company’s stock valued at $306,000 after buying an additional 78 shares in the last quarter. Finally, Yousif Capital Management LLC grew its holdings in Johnson & Johnson by 0.4% during the 4th quarter. Yousif Capital Management LLC now owns 418,520 shares of the company’s stock valued at $73,932,000 after buying an additional 1,852 shares in the last quarter. 67.94% of the stock is owned by hedge funds and other institutional investors.

Johnson & Johnson Stock Down 1.1 %

Shares of JNJ opened at $152.38 on Friday. The company has a market cap of $396.84 billion, a PE ratio of 22.61, a P/E/G ratio of 2.65 and a beta of 0.54. The business has a fifty day moving average of $161.97 and a 200 day moving average of $167.88. Johnson & Johnson has a 52-week low of $150.71 and a 52-week high of $186.69. The company has a quick ratio of 0.77, a current ratio of 0.99 and a debt-to-equity ratio of 0.35.

Johnson & Johnson (NYSE:JNJ – Get Rating) last issued its quarterly earnings results on Tuesday, January 24th. The company reported $2.35 earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of $2.22 by $0.13. The company had revenue of $23.71 billion during the quarter, compared to the consensus estimate of $23.90 billion. Johnson & Johnson had a return on equity of 35.76% and a net margin of 18.90%. Johnson & Johnson’s revenue was down 4.4% on a year-over-year basis. During the same period last year, the company earned $2.13 earnings per share. On average, sell-side analysts expect that Johnson & Johnson will post 10.5 EPS for the current year.

Johnson & Johnson Announces Dividend

The business also recently declared a quarterly dividend, which was paid on Tuesday, March 7th. Investors of record on Tuesday, February 21st were given a $1.13 dividend. The ex-dividend date was Friday, February 17th. This represents a $4.52 dividend on an annualized basis and a yield of 2.97%. Johnson & Johnson’s dividend payout ratio is presently 67.06%.

Insiders Place Their Bets

In other Johnson & Johnson news, insider James D. Swanson sold 1,062 shares of the stock in a transaction on Monday, March 6th. The stock was sold at an average price of $154.66, for a total value of $164,248.92. Following the sale, the insider now owns 9,215 shares in the company, valued at $1,425,191.90. The transaction was disclosed in a legal filing with the SEC, which is accessible through the SEC website. Insiders own 0.35% of the company’s stock.

Wall Street Analysts Forecast Growth

A number of equities research analysts have issued reports on JNJ shares. Atlantic Securities increased their price objective on shares of Johnson & Johnson from $160.00 to $168.00 and gave the company a “neutral” rating in a report on Wednesday, January 25th. Piper Sandler cut their price objective on shares of Johnson & Johnson from $55.00 to $52.00 in a report on Monday, February 6th. StockNews.com started coverage on shares of Johnson & Johnson in a report on Thursday. They set a “strong-buy” rating for the company. Guggenheim started coverage on shares of Johnson & Johnson in a report on Tuesday, February 28th. They set a “neutral” rating and a $161.00 price objective for the company. Finally, SVB Leerink cut their price objective on shares of Johnson & Johnson from $194.00 to $186.00 and set an “outperform” rating for the company in a report on Friday, January 20th. Seven analysts have rated the stock with a hold rating, six have assigned a buy rating and one has issued a strong buy rating to the company. According to data from MarketBeat.com, the stock has an average rating of “Moderate Buy” and a consensus price target of $174.73.

About Johnson & Johnson

(Get Rating)

Johnson & Johnson is a holding company, which engages in the research and development, manufacture and sale of products in the health care field. It operates through the following segments: Consumer Health, Pharmaceutical, and MedTech. The Consumer Health segment includes products focused on personal healthcare used in the Skin Health/Beauty, Over-the-Counter medicines, Baby Care, Oral Care, Women’s Health and Wound Care markets.